CYTO (Altamira Therapeutics Ltd.) Utang jangka cendhak marang modal

Altamira Therapeutics (CYTO) specializes in the development of RNA transport systems. The share price history on GURU.Markets is currently recorded at 0.00. The business relies on the success of licensing agreements and the testing of anti-infective agents. The firm's innovation potential is based on the OligoPhore nanoplatform for the precise distribution of genetic code. Meanwhile, production capacities and cleanroom equipment are functioning without disruption according to the research schedule.

The short-term debt-to-equity ratio measures the proportion of current liabilities within the equity structure, allowing investors to identify hidden liquidity degradation and the risk of asset impairment. By analyzing the dynamics of short-term liabilities relative to equity on GURU.Markets, it can be confirmed that the ideal state of Altamira Therapeutics (CYTO) laboratories and the absence of downtime in RNA research are supported by financial stability rather than critical borrowing.